Skip to Content

New Drug Approvals Archive - November 2012

November 2012

Xeljanz (tofacitinib) Tablets

Date of Approval: November 6, 2012
Company: Pfizer Inc.
Treatment for: Rheumatoid Arthritis

Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

Read more: Xeljanz (tofacitinib) FDA Approval History

Promacta (eltrombopag)

New Indication Approved: November 16, 2012

Read more: Promacta (eltrombopag) FDA Approval History

Flucelvax (influenza virus vaccine)

Date of Approval: November 20, 2012
Company: Novartis
Treatment for: Influenza Prophylaxis

Flucelvax (influenza virus vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza.

Read more: Flucelvax (influenza virus vaccine) FDA Approval History

Cometriq (cabozantinib) Capsules

Date of Approval: November 29, 2012
Company: Exelixis, Inc.
Treatment for: Thyroid Cancer

Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Read more: Cometriq (cabozantinib) FDA Approval History

New Drug Approvals Archive